Alliance for Regenerative Medicine (ARM)

ARM champions the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

3/3
We wish everyone who attended a safe journey home. See you next October for #CGMesa27!

[Alliance for Regenerative Medicine (ARM) @alliancerm]

Day 3 has concluded, and that's a wrap for ARM's 2026 Cell & Gene Meeting on the Mesa! Thank you to our attendees, speakers, and sponsors for three days of candid conversation, new partnerships, and momentum for the sector. #CGMesa26
1/3

[Alliance for Regenerative Medicine (ARM) @alliancerm]

2/3
Even though the conference is over, we still have many favorite moments from the conference that we plan to share over the next few weeks. If you have any you'd like to share, post them using the #CGMesa26.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

2/2
Regulatory confidence has improved, and executives say commercial risk is now investors' top concern, with skepticism about durability being the leading payer barrier to patient access.

Unpack the full survey here: https://t.co/s1cRf7eVnb

[Alliance for Regenerative Medicine (ARM) @alliancerm]

This morning at the #CGMesa26, ARM and Precision For Medicine released a new survey titled "Cell & Gene Therapy Executive Sentiment: Entering the Execution Era."

The report surveyed 44 CGT leaders in August and September. What is the current sentiment?
1/2

[REGENXBIO @REGENXBIO]

We were pleased to attend @alliancerm's #CGMesa26. REGENXBIO CEO Curran Simpson highlighted our differentiated approach to developing one-time treatments for patients and joined fellow industry leaders to discuss safety, access and manufacturing.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

2/2
We're back at it with another full day of panels, workshops, Innovation Spotlights, & partnering. Whether you're in a plenary, on the Partnering Platform, or walking the exhibit area, there's a lot to fit in. We look forward to seeing the energy & excitement ahead for Day 2.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

Day 1 of ARM's #CGMesa26 is in the books!

A big thank you to our speakers who made the first day a smashing success, and another thank you to everyone who turned out for the Networking Bash.
1/2

[Alliance for Regenerative Medicine (ARM) @alliancerm]

4/4
➡️ There remain opportunities to shape the CGT landscape
ARM is undertaking a refreshed, multi-year strategy, organizing our work around the barriers that most limit patient access.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

This morning, ARM CEO Tim Hunt delivered an update on the cell and gene therapy sector during the opening remarks for hashtag#CGMesa26. His overview of the sector's direction can be broken down into three categories...
1/4

[Alliance for Regenerative Medicine (ARM) @alliancerm]

3/4
➡️ Capital is coming back
The 2026 cell and gene therapy investment is significantly outpacing that of 2025.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

Hot off the press at #CGMesa26. ARM member SereNeuro Therapeutics announced the close of its oversubscribed pre-seed financing to support its pre-clinical programs exploring non-opioid therapies for pain. Our congrats to the team!
https://t.co/YKWqdCqaBG

[Alliance for Regenerative Medicine (ARM) @alliancerm]

3/3
Thank you to our supporting organizations, @bmsnews, InspiroGene by @McKesson, @KitePharma, and @LegendBiotech, for helping make this resource possible.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

Another big announcement at #CGMesa26 | https://t.co/l8iAULv9ho is now live! 💻 🧬

Nearly 85% of people with cancer are cared for in community settings, yet fewer than 15% of CAR-T patients are treated outside academic centers.
1/3

[Alliance for Regenerative Medicine (ARM) @alliancerm]

2/3
This is a practical playbook to help hospitals and community practices deliver CAR-T closer to where patients live, from building the business case to reimbursement and long-term follow-up. ARM is delivering this new resource through work with our CAR-T Access Coalition.

[Alliance for Regenerative Medicine (ARM) @alliancerm]

ARM has kicked off #CGMesa26 by announcing the election of our 2027 Board of Directors, including six new directors.

Our congratulations to these distinguished individuals, who will be key to ARM's sector leadership in the year ahead.
https://t.co/3OwMPAZ7gq

[Alliance for Regenerative Medicine (ARM) @alliancerm]

3/3
At the Summit, ARM released our latest Reasons to Believe deck, which lays out these trends and the broader case for the sector, including 2026 seeing more investment return to the sector.

Unpack the full analysis. https://t.co/Aw2QbDA5hQ

[Alliance for Regenerative Medicine (ARM) @alliancerm]

This afternoon, ARM hosted a CEO and Investor Summit at the 2026 Cell & Gene Meeting on the Mesa that brought together cell and gene therapy executives, investors, and analysts to exchange insights on navigating today's capital markets.
1/3
#CGMesa26

[Alliance for Regenerative Medicine (ARM) @alliancerm]

2/3
The day featured panels on CEO insights and investment firms in private and public markets, as well as a fireside chat with Karim Mikhail, Director of FDA CBER.